Ciltacabtagene Autoleucel

• Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy Pending
  2025-524278-40-00 Phase IV 1 country Universitair Ziekenhuis Gent
• A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel Recruiting
  2025-521975-30-00 Phase II 1 country Janssen Cilag International
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom… Recruiting
  2023-507632-20-00 Phase III 9 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel Recruiting
  2023-505530-10-00 Phase IV 4 countries Janssen - Cilag International
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len… Ended
  2023-505850-16-00 Phase III 16 countries Janssen - Cilag International
• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha… Ended
  2023-506588-32-00 Phase III 10 countries Janssen - Cilag International
• An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended
  2023-506587-13-00 Phase II 5 countries Janssen - Cilag International
• Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma Halted
  2023-510560-12-00 Phase II 1 country Fundacion Pethema

Showing 1–8 of 8 trials